{"id":409573,"date":"2021-01-06T09:03:50","date_gmt":"2021-01-06T14:03:50","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409573"},"modified":"2021-01-06T09:03:50","modified_gmt":"2021-01-06T14:03:50","slug":"theralink-technologies-issues-letter-to-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/theralink-technologies-issues-letter-to-shareholders\/","title":{"rendered":"Theralink\u00ae Technologies Issues Letter to Shareholders"},"content":{"rendered":"
\n

Provides a year-end recap and vision for the Company’s path forward<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n

\n DENVER<\/span>, Jan. 6, 2021<\/span> \/PRNewswire\/ — Theralink Technologies<\/b><\/a>\u00a0<\/b>(OTC: OBMP)\u00a0(“Theralink” or the “Company”)<\/b>, a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today issued a letter to shareholders from its President and CEO, Mick Ruxin<\/span>, M.D., providing a 2020 year-end recap and vision for the path ahead in 2021. <\/p>\n

Dear Shareholders:<\/p>\n

2020 was a transformative year for Theralink Technologies. In June, we successfully closed OncBioMune Pharmaceuticals’ asset purchase of Avant Diagnostics and changed the corporate name to Theralink\u00ae Technologies Inc. In September, Theralink emerged as a proteomics-based, molecular profiling and precision medicine company targeting multiple areas of oncology and drug development. Going forward we will continue to work on several other key aspects of our evolution as a public company, including our stock symbol change and updated financial statements with the SEC, which we anticipate to all be completed during the first half of 2021.<\/p>\n

In addition to my appointment as President and CEO, we have added experienced professionals to our leadership team through three key hires. We welcomed Kris Weinberg<\/span> as Director of Commercial Oncology Markets, Michael Fanelli<\/span> as Senior Director of Biopharma Commercial Operations and Tom Chilcott<\/span> as Chief Financial Officer, who all bring extensive experience in their respective fields and have hit the ground running as part of our team.<\/p>\n

Over the past six-months, we have worked diligently to lay the foundation for our growth in 2021. Notably, we received Clinical Laboratory Improvement Amendments (CLIA) certification for our Golden, Colorado<\/span> laboratory, which took two years to achieve. CLIA certification enables us to expand our testing capabilities and we will soon begin receiving, testing and billing for patient’s breast cancer tumor specimens.<\/p>\n

As part of our growth strategy ahead, we have established several strategic agreements: <\/p>\n

In July, we announced a multi-year strategic agreement with VieCure\u2122, the developer of the proprietary VieCure\u2122 platform, a real-time decision-support system that combines clinical knowledge with patient data to assist oncologists in generating personalized treatment plans and managing a patient’s care throughout his or her cancer therapy. Through our agreement, VieCure’s physician network has access to Theralink’s generation of testing for cancer patients, extending VieCure\u2122’s genomics platform to now include phosphoprotein and protein-based information. We believe that the potential reach of their physician network leveraging our assay is substantial. <\/p>\n

In September, we announced our translational research collaboration with BioMed Valley Discoveries (BVD) to provide Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) services to assist BVD with translational research. We believe that this research could potentially improve treatment outcomes and quality of life for all cancer patients. <\/p>\n

In November 2020<\/span>, we announced our agreement with Perthera, a market leader in Precision Oncology technology and services whose platform has been utilized by over 250 cancer care sites. The alliance was formed to facilitate and accelerate access to Theralink’s 32 phosphoprotein panel, the Theralink\u00ae assay, across Perthera’s wide reach in the U.S. for breast cancer patients and the oncologists who treat them.<\/p>\n

With many key milestones under our belt for 2020, there remains no shortage of opportunity as we head into 2021. In addition to the signing of our translational research collaboration with BioMed Valley Discoveries in September 2020<\/span>, we have successfully signed multiple other biopharma collaboration agreements to date, all of which are generating revenue. In 2021, we not only expect to expand these existing relationships, but we will also continue to sign multiple other collaborative agreements.<\/p>\n

Thank you for your continued support and commitment. The Theralink team looks forward to a prosperous 2021!<\/p>\n

Sincerely, <\/p>\n

\n Mick Ruxin<\/span>, M.D.
President and CEO<\/p>\n

\n Corporate Milestones:<\/b>\n <\/p>\n